Table 1 Clinical and pathological characteristics of the included studies
Author | Year | No. of patients | Preoperative chemotherapy | Tumor size (mm) | TNM stage | Comparable variables | Level | Study design | Quality score |
|---|---|---|---|---|---|---|---|---|---|
Knoefel et al. [14] | 2012 | ALPPS(7) PVE(15) | 5 NI | NI | NI | 1, 3, 7 | 4 | RCS | 6 |
Shindoh et al. [19] | 2013 | ALPPS(25) PVE(144) | 12 94 | NI | NI | 1, 2, 5, 7 | 3 | RCS | 7 |
Croome et al. [13] | 2014 | ALPPS(15) PVE(53) | 14 40 | NI | NI | 1, 2, 5, 7, 9 | 3 | RCS | 8 |
Schadde et al. [18] | 2014 | ALPPS(48) PVE/PVL(83) | 28 44 | NI | NI | 1, 2, 4, 5, 7, 8, 9 | 3 | RCS | 9 |
Ratti et al. [16] | 2015 | ALPPS(12) PVE/PVL(36) | 9 30 | NI | NI | 1, 2, 5, 6, 7, 8, 9 | 3 | RCS | 9 |
Matsuo et al. [15] | 2015 | ALPPS(8) PVE(14) | 8 12 | 21 35.5 | NI | 1, 2, 3, 5, 7 | 4 | RCS | 6 |
Tanaka et al. [20] | 2015 | ALPPS(11) PVE/PVL(54) | 11 47 | 22 40.5 | NI | 1, 2, 7 | 4 | RCS | 7 |
Adam et al. [11] | 2016 | ALPPS(17) PVE/PVL(41) | 17 41 | 40 50 | NI | 1, 2, 5, 6, 7, 8 | 4 | RCS | 7 |
Chia et al. [12] | 2017 | ALPPS(10) PVE/PVL(29) | 3 16 | 81 66 | NI | 1, 2, 4, 5, 7 | 4 | RCS | 7 |
Sandström et al. [17] | 2017 | ALPPS(48) PVE/PVL(49) | NI NI | 54 49 | NI | 1, 2, 3, 5, 7, 8, 9 | 1 | RCT | 8 |